Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study)
Francesco Versaci, MD, FACC*,*,
Achille Gaspardone, MPhil, MD, FACC*,
Fabrizio Tomai, MD, FACC*,
Flavio Ribichini, MD
,
Paolo Russo, MD
,
Igino Proietti, MD*,
Anna Silvia Ghini, MD*,
Valeria Ferrero, MD
,
Luigi Chiariello, MD, FACC*,
Pier Agostino Gioffrè, MD¶,
Francesco Romeo, MD, FACC
and
Filippo Crea, MD, FACC||
* Cattedra di Cardiochirurgia, Università Tor Vergata, Rome, Italy
Divisione di Cardiologia, Università del Piemonte Orientale, Novara, Italy
Divisione di Cardiologia, Ospedale S. Croce e Carle, Cuneo, Italy
Cattedra di Cardiologia, Università Tor Vergata, Rome, Italy/AFF
|| Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome, Italy
¶ European Hospital, RomeItaly

View larger version (11K):
[in a new window]
|
Figure 1 Event-free survival (death, myocardial infarction, recurrence of symptoms requiring additional revascularization) curves of the two study groups at 12-month follow-up. The rate of event-free survival was significantly higher in the prednisone group than in the placebo group (p < 0.0016 by Cox proportional hazards regression analysis).
|
|

View larger version (12K):
[in a new window]
|
Figure 2 Cumulative frequency distribution curves showing the percentage of stenosis measured at six-month angiographic follow-up. The vertical broken line indicates the percentage of patients with (right of the line, 33% vs. 7% in placebo [dashed line] and prednisone [solid line] groups, respectively) and without restenosis (left of the line, 67% vs. 93% in placebo and prednisone groups, respectively).
|
|
Copyright © 2002 by the American College of Cardiology Foundation.